Credit Suisse Says AbbVie’s Humira Patent Cliff Could Provide Momentum to Boost Growth

  • Credit Suisse has initiated coverage on AbbVie Inc (NYSE: ABBV) with an Outperform rating and a price target of $170.

  • AbbVie stands on the edge of best-selling Humira’s U.S. loss of exclusivity (LOE) in 2023. While this remains the focus of investor discussions, Credit Suisse sees it as a catalyst to push the narrative from a value story to a growth story.

  • According to Credit Suisse analysts, the management has put the building blocks for growth with Skyrizi, Rinvoq, and aesthetics, which are underappreciated.

  • Related: AbbVie Reports Mixed Earnings, Tightens Guidance, Lifts Quarterly Dividend.

  • Unlike most peers, there is likely limited urgency for business development (BD), given that no other meaningful LOEs are until 2029. Given its strong cash generation and high dividend yield, low valuation is an attractive entry point as management executes on returning to growth in 2024.

  • Price Action: ABBV shares are up 1.80% at $154.895 on the last check Friday.

  • Photo Via Company

Latest Ratings for ABBV

Date

Firm

Action

From

To

Feb 2022

UBS

Downgrades

Buy

Neutral

Feb 2022

Mizuho

Maintains

Buy

Feb 2022

Barclays

Maintains

Equal-Weight

View More Analyst Ratings for ABBV

View the Latest Analyst Ratings

See more from Benzinga

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.